CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DBCR::ABL1Fusion AND ABL1 F317IPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBurgess et al., 2005
DBCR::ABL1Fusion AND ABL1 F317SPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBurgess et al., 2005
DBCR::ABL1Fusion AND ABL1 Q252HPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBurgess et al., 2005
CSMAD4R361CPredisposingSupportsPredispositionJuvenile Polyposis SyndromeHoulston et al., 1998
CVHLF76del (c.227_229del)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLF136S (c.407T>C)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLL153P (c.458T>C)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLP154= (c.462A>C)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLV155G (c.464T>G)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLT157I (c.470C>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLR161G (c.481C>G)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLR161* (c.481C>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLC162F (c.485G>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLC162W (c.486C>G)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLR167L (c.500G>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLL169P (c.506T>C)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLV170G (c.509T>G)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLS183* (c.548C>A)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLL184R (c.551T>G)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLL188R (c.563T>G)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLQ195* (c.583C>T)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLRearrangementPredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseFeletti et al., 2016
CVHLS65L (c.194C>T)OncogenicSupportsOncogenicityRenal CarcinomaGnarra et al., 1994
CVHLL118P (c.353T>C)OncogenicSupportsOncogenicityClear Cell Renal Cell CarcinomaGnarra et al., 1994
CVHLD121_A122del (c.361_366del)OncogenicSupportsOncogenicityClear Cell Renal Cell CarcinomaGnarra et al., 1994
CVHLP138R (c.413C>G)OncogenicSupportsOncogenicityClear Cell Renal Cell CarcinomaGnarra et al., 1994
CVHLN150fs (c.447del)OncogenicSupportsOncogenicityRenal CarcinomaGnarra et al., 1994
CVHLQ164* (c.490C>T)OncogenicSupportsOncogenicityClear Cell Renal Cell CarcinomaGnarra et al., 1994
CABL1C475VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 N336SPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 E453APredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 L387FPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
BBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 Q300RPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 F359IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 F359CPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 E255VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 F486SPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 H396RPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 F359VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 L248VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 E459KPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 A397PPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 F359CPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 E355GPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
Page 93 of 96
PreviousNext